Lilly’s Cyramza succeeds in late-stage liver cancer trial
(Reuters) – Eli Lilly and Co on Wednesday said its drug Cyramza met the main goal of helping patients live longer in a late-stage trial, which tested it as a…
Exclusive – Hospital contract disarray highlights challenges to Saudi healthcare reform
DUBAI (Reuters) – London-listed NMC Health’s (NMC.L) bid to take over the running of a top Saudi hospital has stalled over contractual terms, reflecting wider challenges to the government’s drive…
Ryanair’s 67 percent UK gender pay gap widest among airlines
DUBLIN (Reuters) – Ryanair (RYA.I) has reported an average gender pay gap for its British-based staff of 67 percent, the widest among large airlines that have had to disclose the…
Silicon Valley, Wall Street taking notes on Spotify debut
NEW YORK (Reuters) – Spotify Technology SA’s (SPOT.N) unusual route to becoming a public company is a test case for other multibillion-dollar tech companies that are looking to sell their…
Tesla says no need for capital raise as Model 3 output rises
(Reuters) – Tesla Inc quashed any speculation it might need to raise more capital this year on Tuesday, driving the company’s battered shares higher as it announced it built 2,020…
British passport maker to appeal loss of ‘Brexit blue’ contract
LONDON (Reuters) – The company that makes British passports will challenge the decision to use a foreign firm in future, a government decision that some eurosceptics in the tabloid press…
Wall St. opens higher after tech-led slide
(Reuters) – U.S. stocks rose on Tuesday, recovering from a technology driven selloff a day earlier that pushed the Dow and the S&P 500 below important technical levels amid renewed…
Wall St. opens higher after tech-led slide
(Reuters) – U.S. stocks rose on Tuesday, recovering from a technology driven selloff a day earlier that pushed the Dow and the S&P 500 below important technical levels amid renewed…
Pfizer signs deal with Allogene to develop cancer cell therapy
(Reuters) – Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake,…
FDA refuses to review Alkermes’ depression treatment, seeks more trials
(Reuters) – Alkermes Plc has been told to conduct more clinical trials of its experimental depression treatment after the U.S. Food and Drug Administration rejected its initial application for approval,…